Mediliant SA

Mediliant SA develops and manufactures advanced medical devices, primarily focused on innovative solutions for spine, trauma, and extremity implants, enhancing patient care through precise engineering and automation. Founded in 2013, Mediliant SA operates in Le Locle, Switzerland, specializing in the manufacturing of medical devices aimed at improving patient outcomes. The company has executed a total of one deal, with the most recent deal being on May 23, 2019. Mediliant SA has not undergone significant strategic pivots or structural changes since its inception.

Mediliant SA specializes in the contract manufacturing of medical devices, primarily focusing on spine, trauma, and extremity implants. The company employs precision technology and advanced automation processes to deliver high-quality products tailored to the needs of healthcare providers and medical device companies. Their core offerings include surgical implants that improve patient outcomes in orthopedic procedures, addressing various medical conditions. Their clientele consists of both large healthcare organizations and small medical device firms, allowing the company to have a broad impact within the healthcare sector.

The products are designed for distribution across Europe, North America, and other regions. Mediliant SA generates revenue primarily through B2B transactions, supplying medical devices to hospitals, healthcare providers, and medical technology companies. Sales typically involve direct partnerships where clients place bulk orders for specific implant products, thus ensuring stable revenue streams through long-term contracts. While specific pricing plans are not disclosed, transactions are structured around negotiated agreements that cater to the varying needs of their diverse client base.

The flagship products represent the company’s commitment to quality and efficiency in orthopedic manufacturing, with a strong focus on customer service excellence enhancing client retention and repeat business. Mediliant SA is focusing on developing new products aimed at enhancing its portfolio in orthopedic solutions. The company plans to expand into new markets, with specific targets set for Europe and North America by 2024. Recent funding, marked by the acquisition of a minority stake by Ekkio Capital in May 2019, will be utilized to support these initiatives, ensuring they can enhance product development and market reach.